NewSquare Capital LLC Purchases 3,150 Shares of Merck & Co., Inc. $MRK

NewSquare Capital LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 5.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,449 shares of the company’s stock after purchasing an additional 3,150 shares during the quarter. NewSquare Capital LLC’s holdings in Merck & Co., Inc. were worth $5,163,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Legend Financial Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $25,000. CBIZ Investment Advisory Services LLC grew its stake in Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after purchasing an additional 221 shares during the period. Fiduciary Wealth Partners LLC acquired a new stake in Merck & Co., Inc. during the first quarter worth approximately $48,000. MJT & Associates Financial Advisory Group Inc. acquired a new stake in Merck & Co., Inc. during the first quarter worth approximately $48,000. Finally, Mountain Hill Investment Partners Corp. acquired a new stake in Merck & Co., Inc. during the second quarter worth approximately $43,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $82.51 on Tuesday. The business’s fifty day simple moving average is $84.51 and its 200 day simple moving average is $81.89. The firm has a market capitalization of $206.09 billion, a P/E ratio of 12.71, a price-to-earnings-growth ratio of 0.95 and a beta of 0.37. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $105.07. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.36 by $0.22. The firm had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business’s revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.57 earnings per share. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research reports. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 price objective for the company. Morgan Stanley raised their price objective on Merck & Co., Inc. from $98.00 to $100.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $104.47.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.